Good MorningEquity markets rebounded for another day on Thursday as traders gear up for the Q2 earnings reporting season. The peak of the season begins next week with reports from the big banks and the news is expected to be dismal. At best, the banks will report tepid growth with a high likelihood of earnings contraction. The contraction will be due in large part to increased credit reserves in the face of an oncoming recession, the question is how big will the build-up be?
Friday action will be dominated by the NFP report which is expected to show a slowdown in job gains. The question here regards wages and how fast earnings are growing? While good for the average new job taker the persistent increase in labor costs is bad news for businesses and consumers. Next week, investors will have a wave of economic data to wade through including the CPI for June and Retail Sales. Featured: Ukraine isn't the real problem - Taiwan is. (BehindtheMarkets) 
|
Markets | | | While insider buying is no guarantee for higher share prices it is certainly an indication of optimism and value in a stock. This is why we like to scope out the insider-buying data, it’s a valuable source for trading ideas. Read the Full Story |
|
From Our PartnersOne company has taken the subscription model of streaming services and applied it to a surprising industry...
One expert believes: "This Stock Under $2 Could Hit $20 in the Years Ahead..."
WARNING: If you aren't in by August, 2022 - your chance could be gone forever. | | View the Shocking Details Here |
|
Politics | | | Stocks rose broadly on Wall Street in afternoon trading Thursday, extending a winning streak that has the market on pace for a weekly gain.
The S&P 500 rose 1.4% as of 2:36 p.m. Eastern. Roughly 75% of the stocks in the benchmark index rose. The Dow Jones Industrial Average rose ... Read the Full Story |
|
Markets | | | Now’s a good time to see if there are perhaps overlooked stocks that are worth consideration. We think that Micron (NASDAQ: MU), with its huge addressable market and cemented product leader position, could be one such stock. Let’s take a look at some of the reasons why. Read the Full Story |
|
From Our PartnersA former advisor to the CIA and Pentagon believes this order could allow for legal government surveillance of all US citizens; total control over your bank accounts and purchases; and the ability to silence all dissenting voices for good. | | | | See what Biden signed in Executive Order 14067 |
|
Politics | | | Fifty-nine people went on trial Thursday for the 2018 collapse of Genoa’s Morandi bridge, accused of manslaughter and other charges in the deaths of 43 people.
The defendants include former executives and technical experts of the company that manages many of Italy’s bridges and highwa... Read the Full Story |
|
Tech | | | Data infrastructure networking solutions and licenses provider Credo Technology (NASDAQ: CRDO) stock is only down a merciful (-3%) for the year. It’s worth noting that the fabless semiconductor company only recently IPO’ed in January of 2022 but shares have been resilient due to its stro... Read the Full Story |
|
From Our PartnersEx-Wall Street CEO Dylan Jovine is one of the best Small-Cap investors on earth.
He's delivered 435% profits on ChemoCentrix, 220% returns on Editas, 159% profits with Magnolia, Gas and 194% with Scotts Miracle Gro. | | Get his #1 Small-Cap for July here > > > |
|
Markets | | | The European Union's plan to include natural gas in a list of activities considered sustainable could derail its progress in reducing greenhouse gas emissions at a time when climate scientists are calling for dramatic reductions to planet-warming releases.
The plan, approved Wednesday... Read the Full Story |
|
Markets | | | We recently saw some coverage of Roblox (NASDAQ: RBLX) that led us to believe it could be a great play for the 2nd half. The story suggested a recent pop in share prices was due to increased retail chatter that may lead to a short-squeeze, it even suggested Roblox could be a meme stock but we don't think so. Read the Full Story |
|
Stocks | | | Samsung (OTC: SSNLF) reported a mixed quarter but details within the report are lifting the chip sector. While the news may have sparked a near-term bottom we’re not sure it will stick. The company reported a stronger-than-expected demand for memory chips which is good news but the demand was limited to cloud and server applications. Read the Full Story |
|
Markets | | | The nation's largest food distributor has joined the other businesses accusing the four largest meat processors of working together to inflate beef prices.
Sysco recently filed a federal lawsuit in Texas accusing Tyson Foods, JBS, Cargill and National Beef of price fixing. The lawsuit... Read the Full Story |
|
Politics | | | Senate Democrats want to boost taxes on some high earners and use the money to extend the solvency of Medicare, the latest step in the party's election-year attempt to craft a scaled-back version of the economic package that collapsed last year, Democratic aides told The Associated Press.
... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
